Authorized purpose: Automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from MR images, with comparison to reference percentile data; not intended for clinical scenarios requiring evaluation of the number of white matter hyperintensities.
Clinical role
Post-acquisition DICOM pipeline that retrieves 3D T1 and T2 FLAIR data, performs automated brain and lesion segmentation and quantification, generates a report and overlays, and supports trained-physician review and editing.
Images and patients
MRI · Brain structures and lesions, including grey matter, white matter, hippocampus, amygdala, and white matter hyperintensities
Key limitation
Keep in mind: The intended use excludes clinical scenarios requiring evaluation of the number of white matter hyperintensities. The described input population is ages 20-90 with specified T1/T2 FLAIR protocols and field strengths, and results must be reviewed by a trained physician. The packet supports Linux and off-the-shelf hardware but does not establish every scanner or local configuration.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from MR images, with comparison to reference percentile data; not intended for clinical scenarios requiring evaluation of the number of white matter hyperintensities.
Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain structures and lesions, including grey matter, white matter, hippocampus, amygdala, and white matter hyperintensities Input: DICOM MRI data with 3D T1 and T2 FLAIR series from patients aged 20 to 90; T1 processing supports 1.5T and 3T scanners and T2 FLAIR processing supports 3T scanners.
Who uses it?Intended users: Medical personnel or neuroimaging-trained personnel, with review by a trained physician.
What does the software produce?Output: Volumetric measurements of brain structures and lesions, segmented color overlays, electronic morphometric/PDF reports, comparisons with a healthy reference population and prior scans when available, and DICOM output viewable on DICOM workstations and PACS.
What is its most important limitation?Key limitation: The intended use excludes clinical scenarios requiring evaluation of the number of white matter hyperintensities. The described input population is ages 20-90 with specified T1/T2 FLAIR protocols and field strengths, and results must be reviewed by a trained physician. The packet supports Linux and off-the-shelf hardware but does not establish every scanner or local configuration.
Clinical takeaway. Clinical role: Automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from MR images, with comparison to reference percentile data; not intended for clinical scenarios requiring evaluation of the number of white matter hyperintensities.
Evidence takeaway. Evidence from the reviewed source record: FDA performance testing included software verification, validation, human-factors testing, literature-based validation studies stated in the submission, and segmentation-accuracy evaluation. For 3D T1 brain structures, Dice coefficients exceeded 85% for whole-brain regions and ranged from 75% to 85% for subcortical structures. Lesion segmentation on paired 3D T1 and T2 FLAIR sequences reported mean absolute volume difference 3.34 mL over lesion loads from 0.09 mL to 87.65 mL. These are segmentation overlap and volume-difference endpoints, not sensitivity or specificity.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from MR images, with comparison to reference percentile data; not intended for clinical scenarios requiring evaluation of the number of white matter hyperintensities.
Post-acquisition DICOM pipeline that retrieves 3D T1 and T2 FLAIR data, performs automated brain and lesion segmentation and quantification, generates a report and overlays, and supports trained-physician review and editing.
DICOM MRI data with 3D T1 and T2 FLAIR series from patients aged 20 to 90; T1 processing supports 1.5T and 3T scanners and T2 FLAIR processing supports 3T scanners.
Volumetric measurements of brain structures and lesions, segmented color overlays, electronic morphometric/PDF reports, comparisons with a healthy reference population and prior scans when available, and DICOM output viewable on DICOM workstations and PACS.
The intended use excludes clinical scenarios requiring evaluation of the number of white matter hyperintensities. The described input population is ages 20-90 with specified T1/T2 FLAIR protocols and field strengths, and results must be reviewed by a trained physician. The packet supports Linux and off-the-shelf hardware but does not establish every scanner or local configuration.
FDA performance testing included software verification, validation, human-factors testing, literature-based validation studies stated in the submission, and segmentation-accuracy evaluation. For 3D T1 brain structures, Dice coefficients exceeded 85% for whole-brain regions and ranged from 75% to 85% for subcortical structures. Lesion segmentation on paired 3D T1 and T2 FLAIR sequences reported mean absolute volume difference 3.34 mL over lesion loads from 0.09 mL to 87.65 mL. These are segmentation overlap and volume-difference endpoints, not sensitivity or specificity.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA performance testing included software verification, validation, human-factors testing, literature-based validation studies stated in the submission, and segmentation-accuracy evaluation. For 3D T1 brain structures, Dice coefficients exceeded 85% for whole-brain regions and ranged from 75% to 85% for subcortical structures. Lesion segmentation on paired 3D T1 and T2 FLAIR sequences reported mean absolute volume difference 3.34 mL over lesion loads from 0.09 mL to 87.65 mL. These are segmentation overlap and volume-difference endpoints, not sensitivity or specificity.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
QyScore Software regulatory performance study summary
DesignStand-Alone Performance
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K192531
IndependenceIndependence not established
K192531
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K192531. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM MRI data with 3D T1 and T2 FLAIR series from patients aged 20 to 90; T1 processing supports 1.5T and 3T scanners and T2 FLAIR processing supports 3T scanners.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The software retrieves DICOM MRI data from a DICOM server, sends it to an analysis server, and supports DICOM output for DICOM workstations and PACS; it also states integration with leading RIS/PACS systems without establishing a specific product, version, or local compatibility.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes software that operates on off-the-shelf hardware and sends DICOM MRI data retrieved from a DICOM server to an analysis server for automatic segmentation. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Both devices are DICOM compatible and operate on off-the-shelf hardware." … "The software retrieves DICOM MRI data (3DT1 and T2FLAIR series) from a DICOM server and sends it to an analysis server for automatic segmentation". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Volumetric measurements of brain structures and lesions, segmented color overlays, electronic morphometric/PDF reports, comparisons with a healthy reference population and prior scans when available, and DICOM output viewable on DICOM workstations and PACS.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Volumetric measurements of brain structures and lesions, segmented color overlays, electronic morphometric/PDF reports, comparisons with a healthy reference population and prior scans when available, and DICOM output viewable on DICOM workstations and PACS.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes software that operates on off-the-shelf hardware and sends DICOM MRI data retrieved from a DICOM server to an analysis server for automatic segmentation. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Both devices are DICOM compatible and operate on off-the-shelf hardware." … "The software retrieves DICOM MRI data (3DT1 and T2FLAIR series) from a DICOM server and sends it to an analysis server for automatic segmentation". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The software retrieves DICOM MRI data from a DICOM server, sends it to an analysis server, and supports DICOM output for DICOM workstations and PACS; it also states integration with leading RIS/PACS systems without establishing a specific product, version, or local compatibility.
The 510(k) summary's subject-device safety characteristics state that results must be reviewed by a trained physician, and the summary states QyScore is used by medical personnel or neuroimaging trained personnel.
Exact FDA submission
Checked 2026-10-27
User qualification wording only; the summary specifies no training program or training offering for this device.
ACR AI Central provides an exact-submission model card for QyScore Software; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
9Source classes checked
2Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 2 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K192531 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
Authorized purpose: Neurophet AQUA is intended for automatic labeling, visualization, and volumetric quantification of segmentable brain structures and lesions from a set of MR images; volumetric data may be compared to reference percentile data.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Authorized purpose: Post-process previously acquired cervical-spine MR images to segment vertebrae and disks, calculate quantitative measurements, label out-of-range values, and export results for user review and interpretation.
Modality
MRI
Anatomy
Cervical spine: vertebrae C3-C7 and disks C2C3 through C7T1
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.